Brucellosis primary prevention

Revision as of 06:44, 30 August 2012 by WikiBot (talk | contribs) (Created page with "__NOTOC__ {{Brucellosis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{CMG}}; {{AE}} {{RT}} ==O...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Brucellosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Brucellosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Principles of diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT Scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Brucellosis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Brucellosis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Brucellosis primary prevention

CDC on Brucellosis primary prevention

Brucellosis primary prevention in the news

Blogs on Brucellosis primary prevention

Directions to Hospitals Treating Brucellosis

Risk calculators and risk factors for Brucellosis primary prevention

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Primary Prevention

To prevent brucellosis, unpasteurized milk, cheese, or ice cream should be avoided while traveling. IHunters and animal herdsman should use rubber gloves when handling viscera of animals. There is no vaccine available for humans.

Biological warfare

In 1954, B. suis became the first agent weaponized by the U.S. at its Pine Bluff Arsenal in Arkansas. Brucella species survive well in aerosols and resist drying. Brucella and all other remaining biological weapons in the US arsenal were destroyed in 1971-72 when the U.S. offensive biological weapons (BW) program was discontinued. [1]

The United States BW program focused on three agents of the Brucella group:

  • Porcine Brucellosis (Agent US)
  • Bovine Brucellosis (Agent AB)
  • Caprina Brucellosis (Agent AM)

Agent US was in advanced development by the end of the Second World War. When the USAF wanted a biological warfare capability, the Chemical Corps offered agent US in the M114 bomblet, based after the 4-pound bursting bomblet developed for anthrax in the Second World War. Though the capability was developed, operational testing indicated that the weapon was less than desirable, and the USAF termed it an interim capability until replaced by a more effective biological weapon. The main drawbacks of the M114 with agent US was that it was incapacitating (the USAF wanted "killer" agents), the storage stability was too low to allow for storing at forward air bases, and the logistical requirements to neutralize a target were far higher than originally anticipated, requiring unreasonable logistical air support.

Agents US and AB had a median infective dose of 500 org/person, and AM was 300 org/person. The rate-of-action was believed to be 2 weeks, with a duration of action of several months. The lethality estimate was based on epidemiological information at 1 - 2%. AM was always believed to be a more virulent disease, and a 3% fatality rate was expected.

Reference

  1. Woods, Lt Col Jon B. (ed.) (April 2005). USAMRIID’s Medical Management of Biological Casualties Handbook (6th ed. ed.). U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Maryland. p. 53. External link in |title= (help)